GTCM
FULC icon

Gyon Technologies Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Gyon Technologies Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,534
Closed -$275K – 381
2021
Q4 		$275K Buy
+15,534
New +$308K 0.05% 440

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gyon Technologies Capital Management's FULC Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Fulcrum Therapeutics (FULC) in Q1 2022, closing a stake of 15,534 shares — an estimated $275K sold.

Gyon Technologies Capital Management first reported a position in FULC in Q4 2021 and held it in 1 quarter. The position peaked at $275K in Q4 2021. 108 funds tracked by Wall St. Rank hold FULC as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Fulcrum Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 15,534 Fulcrum Therapeutics shares in Q1 2022, an estimated $275K.
  • Gyon Technologies Capital Management first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Fulcrum Therapeutics position peaked at $275K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.